Movement Alert｜BEIGENE Rises 3.33% in Regular Trading, Nomura Raises Target Price to HK$270.74 Boosting Sentiment

Market Focus07-29 09:33

On July 29, BEIGENE rose 3.33% in regular trading, trading at HK$200.0/share, with turnover of HK$54.25 million, reversing the prior session's over 3% decline.

On the news front, Nomura recently issued a research report raising BEIGENE's target price to HK$270.74, forecasting a 74% year-over-year increase in operating profit for the second quarter. Additionally, Huafu Securities initiated coverage with a \"Buy\" rating and a target price of HK$297.44, highlighting the company's entry into a new era of multi-curve growth. The company also recently announced an additional US$300 million investment to expand its U.S. manufacturing base and clinical R&D center. Coupled with positive progress from Brukinsa's MANGROVE Phase 3 clinical trial meeting its primary endpoint of progression-free survival, fundamental catalysts continue to emerge ahead of the August 5 earnings release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161142211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161142211","market":"us","top_or_hot":-1,"title":"Movement Alert｜BEIGENE Rises 3.33% in Regular Trading, Nomura Raises Target Price to HK$270.74 Boosting Sentiment","media":"Market Focus","content":"<p><p>On July 29, BEIGENE rose 3.33% in regular trading, trading at HK$200.0/share, with turnover of HK$54.25 million, reversing the prior session's over 3% decline.</p><p>On the news front, Nomura recently issued a research report raising BEIGENE's target price to HK$270.74, forecasting a 74% year-over-year increase in operating profit for the second quarter. Additionally, Huafu Securities initiated coverage with a \\\"Buy\\\" rating and a target price of HK$297.44, highlighting the company's entry into a new era of multi-curve growth. The company also recently announced an additional US$300 million investment to expand its U.S. manufacturing base and clinical R&D center. Coupled with positive progress from Brukinsa's MANGROVE Phase 3 clinical trial meeting its primary endpoint of progression-free survival, fundamental catalysts continue to emerge ahead of the August 5 earnings release.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEIGENE Rises 3.33% in Regular Trading, Nomura Raises Target Price to HK$270.74 Boosting Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEIGENE Rises 3.33% in Regular Trading, Nomura Raises Target Price to HK$270.74 Boosting Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-29 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 29, BEIGENE rose 3.33% in regular trading, trading at HK$200.0/share, with turnover of HK$54.25 million, reversing the prior session's over 3% decline.</p><p>On the news front, Nomura recently issued a research report raising BEIGENE's target price to HK$270.74, forecasting a 74% year-over-year increase in operating profit for the second quarter. Additionally, Huafu Securities initiated coverage with a \\\"Buy\\\" rating and a target price of HK$297.44, highlighting the company's entry into a new era of multi-curve growth. The company also recently announced an additional US$300 million investment to expand its U.S. manufacturing base and clinical R&D center. Coupled with positive progress from Brukinsa's MANGROVE Phase 3 clinical trial meeting its primary endpoint of progression-free survival, fundamental catalysts continue to emerge ahead of the August 5 earnings release.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1161142211","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161142211","pubTimestamp":1785288785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, BEIGENE rose 3.33% in regular trading, trading at HK$200.0/share, with turnover of HK$54.25 million, reversing the prior session's over 3% decline.On the news front, Nomura recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势警报|百济神州常规交易上涨3.33%，野村证券将目标价上调至270.74港元，提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On July 29, BEIGENE rose 3.33% in regular trading, trading at HK$200.0/share, with turnover of HK$54.25 million, reversing the prior session's over 3% decline.On the news front, Nomura recently issued a research report raising BEIGENE's target price to HK$270.74, forecasting a 74% year-over-year increase in operating profit for the second quarter. Additionally, Huafu Securities initiated coverage with a \\\"Buy\\\" rating and a target price of HK$297.44, highlighting the company's entry into a new era of multi-curve growth. The company also recently announced an additional US$300 million investment to expand its U.S. manufacturing base and clinical R&D center. Coupled with positive progress from Brukinsa's MANGROVE Phase 3 clinical trial meeting its primary endpoint of progression-free survival, fundamental catalysts continue to emerge ahead of the August 5 earnings release.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161142211","isCrawlerRequest":true}